English | Français
English | Français
A first-in-class acellular regenerative biologic
ICB001 is the lead product candidate developed by iC BIOSOLUTIONS.
It is a concentrated, acellular secretome, designed to modulate inflammation and support tissue regeneration through the bioactive signals naturally released by stem cells.
As the first clinical application of the iC BIOSOLUTIONS secretome platform, ICB001 establishes a new class of regenerative biologics that overcomes the limitations of traditional cell-based therapies.
Product type
Acellular secretome-based biologic
Product scope
A versatile secretome-based biologic designed to address selected chronic inflammatory conditions across multiple veterinary species through indication-specific development programs.
First indication
Reduction of lameness associated with non-septic joint diseases in horses.
Clinical use & administration
Off-the-shelf, stable product for local administration.
Therapeutic class
First-in-class secretome-based regenerative biologic.
ICB001 is an acellular secretome-based therapeutic that delivers the bioactive signals responsible for the therapeutic effects of stem cells, but in a controlled, standardized, and reproducible format.
This design enables the biological benefits of stem–cell signaling to be transformed into a product compatible with clinical use, scalable manufacturing, and regulatory requirements.
ICB001 is manufactured using the iC BIOSOLUTIONS proprietary development platform, combining:
This approach ensures consistent product quality, scalable manufacturing, and alignment with regulatory standards across development stages.
Safety by design
A cellular composition derived from GMP-compliant stem cell banks, minimizing the risks associated with administrating viable cells.
Consistent potency and composition
Controlled production ensures reproducible secretome profiles and reliable therapeutic activity.
Clinical and operational simplicity
An off-the-shelf, shelf-stable formulation enables straightforward storage, handling, and administration.
ICB001 acts through paracrine regenerative signaling, modulating key biological pathways involved in inflammation control and tissue recovery.
Its activity is based by:
These mechanisms are highly conserved across mammalian species and tissues, supporting both the translational relevance of the equine clinical models and the broad applicability secretome-based therapeutics.
Why Equine Joint diseases?
Equine joint diseases, including osteoarthritis, represent a major unmet medical need, with limited disease-modifying treatment options.
Starting in equine medicine enables:
Clinical development status & market-authorization pathway
ICB001 is currently advancing through clinical development in horses, with studies designed to support regulatory approval in veterinary medicine.